Dr. Mark Goodwin brings advanced cardiac cath lab technology to region
WALTHAM, MA - December 16, 2015 – Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, today announced that Edward Heart Hospital has become the first facility in the state of Illinois to perform procedures with the CorPath System, the first FDA-cleared medical device for robotically-assisted percutaneous coronary interventions (PCI).
"From our first case, we've used the CorPath System to successfully perform complex PCI," said Mark Goodwin, MD, Chief of Cardiology, Edward Heart Hospital. "Our whole team is very excited to be leaders in bringing this technology to our patients and this protection to our staff."
"With the CorPath System, the physicians at Edward Heart Hospital are able to leverage robotic precision and protection for their expanding practice and complex case load," stated David Handler, President and Chief Executive Officer of Corindus. "Edward Hospital has always been a leader in interventional cardiology procedures and technology. We are very pleased to be working with them and to have such a prestigious Chicago hospital using our technology."
Interventional procedures performed in hospital cath labs are a leading source of radiation exposure for medical personnel and have been linked to the development of cataracts, cancer, and brain and thyroid diseases. The CorPath System allows interventional cardiologists to perform the procedure away from the patient bed side and the radiation source. Seated in a radiation-protected cockpit, the physician uses digital controls to robotically advance catheters, angioplasty balloons and stents to clear the blockage in the heart and restore blood flow. Additionally, the technology provides interventional cardiologists with the ability to accurately measure relevant anatomy, which may lead to fewer stent implants.
For additional information, visit www.corindus.com and follow @CorindusInc.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."
For additional information, visit www.corindus.com, and follow @CorindusInc.
Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event
Examples of such statements include statements: